Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial

Journal of Infectious Diseases

Volumn 189, Issue 2, 2004, Pages 265-272

  Eron, Joseph J ^a   Feinberg, Judith ^b   Kessler, Harold A ^c   Horowitz, Harold W ^e   Witt, Mallory D ^g   Carpio, Felix F ^h   Wheeler, David A ^j   Ruane, Peter ⁱ   Mildvan, Donna ^f   Yangco, Bienvenido G ^k   Bertz, Richard ^d   Bernstein, Barry ^d   King, Martin S ^d   Sun, Eugene ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e WESTCHESTER MEDICAL CENTER   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h AltaMed Health Services Corporation   (United States)

ⁱ Tower Infectious Diseases ^*  (United States)

^j Infectious Diseases Physicians   (United States)

^k INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS REPLICATION; WILD TYPE;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRIMIDINONES; RITONAVIR;

EID: 9144233476     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380799     Document Type: Article

References (24)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14:2129-36.
3. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-72.
4. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
5. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine- zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285:1155-63.
6. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
8. Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001; 15:2379-84.
9. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-3.
10. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
11. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-77.
12. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998; 250:255-62.
13. Murphy R, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-9.
14. + patients: 4-year follow-up [abstract H-165). In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:261.
15. Lal R, Hsu A, Granneman R, et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir [abstract 647]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:201.
16. Hirsch MS, Brun-Vezinet F, D'Aquilla RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA panel. JAMA 2000; 283:2417-26.
17. Centers for Diseases Control and Prevention. 1993 Revised classification system for HIV infection and expanded case surveillance definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
18. Agenerase (amprenavir) [product information insert]. Research Triangle Park, NC: GlaxoSmithKline, 2002.
19. Mars ME, Trylesinski A, Loi S, Suzan V, Gallais H. Fortovase-ritonavir qd used after a first protease inhibitor therapy in HIV infected patient with virologic failure [poster 676.]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001:282.
20. + patients: 72 week follow up [poster TuPeB4445.]. In: Program and abstracts of the XIV International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:378.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-597.
22. Kumar P, Rodriguez-French A, Thompson M. Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TQ/NFV (ESS40002) [abstract 33]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:64.
23. Gallant J, Staszewski S, Pozniak A, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART) naïve patients: a 48 week interim analysis [abstract LB-2], In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:8 (appendix).
24. 50 [abstract 4.2]. In: Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy (Cannes). Utrecht: Virology-Education BV, 2003:11-2.